- Terapie inhibitory PCSK9 u pacientů se statinovou intolerancí2019 | First Faculty of Medicine
- Co přinesla studie FOURIER? Důkazy pro inhibitory PCSK9, nebo "jen" potvrdila LDL hypotézu?2017 | First Faculty of Medicine
- Slibný perorální inhibitor PCSK9 ve vývoji2023 | First Faculty of Medicine
- Ezetimibe and combination of lipid lowering medications: what is their role in the era of PCSK9 inhibitors?2017 | First Faculty of Medicine
- PCSK9 inhibitors in light of recent data2016 | First Faculty of Medicine
- New possibilities of dyslipidemiaa therapy in patients with familial hypercholesterolemia in secondary prevention - change in reimbursement for PCSK9 inhibitors2021 | First Faculty of Medicine
- Comments on the most important and recent studies involving PCSK9i2018 | First Faculty of Medicine
- The treatment of hypercholesterolemia by PCSK9 inhibitors2014 | Faculty of Medicine in Hradec Králové
- The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?2018 | Faculty of Medicine in Hradec Králové
- Inhibitors PCSK9 - experience after two years of practice in the Czech Republic2017 | Faculty of Medicine in Hradec Králové
- Nová hypolipidemika a jejich vliv na cévní stěnu a kardiovaskulární riziko2017 | Faculty of Medicine in Pilsen
- First impressions of the ODYSSEY Outcomes trial2018 | First Faculty of Medicine
- Turn in hypercholesterolemia treatment - PCSK9 inhibitors. What we know about the alirocumab (product Praluent(R)) yet?2016 | First Faculty of Medicine
- Lipid lowering therapy - proven treatment options and prospects for the near future2022 | First Faculty of Medicine
- Evolocumab, proproteine convertase subtilisin/kexin type 9 inhibitor for intensive treatment of dyslipidemia2016 | Faculty of Medicine in Pilsen
- Biologická léčba hypercholesterolemie2017 | First Faculty of Medicine
- Několik vět ke studii ODYSSEY Outcomes2018 | First Faculty of Medicine
- Alirocumab, human monoclonal antibody in biological dyslipidemia treatment2016 | Faculty of Medicine in Pilsen
- Indication of PCSK9 inhibitors in the expert view of the CSAT2016 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Komentář k "Praktickému doporučení pro použití PCSK9-inhibitorů" aneb Proč renomovaní autoři píší dokumenty, které si samy odporují2018 | First Faculty of Medicine
- News in pharmacotherapy dyslipidemia2014 | First Faculty of Medicine
- Combination therapy for dyslipidemia2014 | First Faculty of Medicine
- Treatment of dyslipidemias - questionaires, and the future2016 | First Faculty of Medicine
- Hyperlipoprotienemias and (not only) atherosclerosis: fragments from history and present fragments from history and present2017 | First Faculty of Medicine
- Hypolipidemická léčba u pacientů s chronickým onemocněním ledvin2022 | First Faculty of Medicine
- New treatment possibilities of homozygous familial hypercholesterolemia2023 | Faculty of Medicine in Hradec Králové
- Přehled hypolipidemik2018 | First Faculty of Medicine
- Contemporary and modern treatment of hyperlipoproteinemia2016 | First Faculty of Medicine
- New lipid lowering drugs2021 | First Faculty of Medicine
- Biological therapy in cardiology - New studies with antibodies directed against PCSK92015 | First Faculty of Medicine